Abstract

<div>Abstract<p>microRNAs are short noncoding RNAs that regulate protein expression posttranscriptionally. We previously showed that miR-155 promotes effector CD8<sup>+</sup> T-cell responses. However, little is known about the regulation of miR-155 expression. Here, we report that antigen affinity and dose determine miR-155 expression in CD8<sup>+</sup> T cells. In B16 tumors expressing a low-affinity antigen ligand, tumor-specific infiltrating CD8<sup>+</sup> T cells showed variable miR-155 expression, whereby high miR-155 expression was associated with more cytokine-producing cells and tumor control. Moreover, anti–PD-1 treatment led to both increased miR-155 expression and tumor control by specific CD8<sup>+</sup> T cells. In addition, miR-155 overexpression enhanced exhausted CD8<sup>+</sup> T-cell persistence in the LCMV cl13 chronic viral infection model. In agreement with these observations in mouse models, miR-155 expression in human effector memory CD8<sup>+</sup> T cells positively correlated with their frequencies in tumor-infiltrated lymph nodes of melanoma patients. Low miR-155 target gene signature in tumors was associated with prolonged overall survival in melanoma patients. Altogether, these results raise the possibility that high miR-155 expression in CD8<sup>+</sup> tumor-infiltrating T cells may be a surrogate marker of the relative potency of <i>in situ</i> antigen-specific CD8<sup>+</sup> T-cell responses.</p></div>

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call